近日,美国食品药品管理局(FDA)批准lifitegrast滴眼液(Xiidra)为首个可用于干眼症治疗的新型淋巴细胞功能相关抗原拮抗剂类药物。干眼症伴有一系列症状包括泪液减少或泪液量异常等,其发病率与年龄增长呈正相关,在30~40岁的 Recently, the US Food and Drug Administration (FDA) approved lifitegrast eye drops (Xiidra) as the first new type of lymphocyte function-related antigen antagonist for the treatment of dry eye syndrome. Dry eye syndrome associated with a series of symptoms including decreased tear or tear abnormalities, the incidence was positively correlated with age, in 30 to 40 years of age